Enhanced DNA Repair as a Mechanism of Resistance to cis-Diamminedichloroplatinum(II)

Biochemistry

Volumn 27, Issue 13, 1988, Pages 4730-4734

  Eastman, Alan ^a   Schulte, Nancy ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; TRITIUM;

CELL CULTURE; DNA DAMAGE; DNA REPAIR; DRUG ACCUMULATION; DRUG BINDING; DRUG SENSITIVITY; ISOTOPE LABELING; LEUKEMIA L 1210; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMAL; CISPLATIN; DNA DAMAGE; DNA REPAIR; DNA, NEOPLASM; DRUG RESISTANCE; KINETICS; LEUKEMIA L1210; MICE; SUPPORT, U.S. GOV'T, P.H.S.;

EID: 0023718434     PISSN: 00062960     EISSN: 15204995     Source Type: Journal    
DOI: 10.1021/bi00413a022     Document Type: Article

References (25)

1. Andrews, P. A., Murphy, M. P., & Howell, S. B. (1986) Proc. Am. Assoc. Cancer Res. 27, 289.
2. Beck, D. J., & Brubaker, R. R. (1973) J. Bacteriol. 116, 1247–1252.
3. Behrens, B. C., Hamilton, T. C., Masuda, H., Grotzinger, K. R., Whang-Peng, J., Louie, K. G., Knutsen, T., McKoy, W. M., Young, R. C., & Ozols, R. F. (1987) Cancer Res. 47, 414–418.
4. Drobnik, J., Urbankova, M., & Krekulova, A. (1973) Mutat. Res. 17, 13–20.
5. Eastman A. (1983) Biochemistry 22, 3927–3933.
6. Eastman, A. (1986) Biochemistry 25, 3912–3915.
7. Eastman, A. (1987a) Pharmacol. Ther. 34, 155–166.
8. Eastman, A. (1987b) Chem.-Biol. Interact. 61, 241–248.
9. Eastman, A., & Bresnick, E. (1981) Biochem. Pharmacol. 30, 2721–2723.
10. Eastman, A., Mossman, B. T., & Bresnick, E. (1982) Carcinogenesis (London) 3, 1283–1287.
11. Eastman, A., & Richon, V. M. (1986) in Biochemical Mechanisms of Platinum Antitumor Drugs (McBrien, D. C. H., & Slater, T. F., Eds.) pp 91–119, IRL, Oxford.
12. Fichtinger-Schepman, A. M. J., van der Veer, J. L., den Hartog, J. H. J., Lohman, P. H. M., & Reedijk, J. (1985) Biochemistry 24, 707–713.
13. Fraval, H. N. A., Rawlings, C. J., & Roberts, J. J. (1978) Mutat. Res. 57, 121–132.
14. Hamilton, T. C., Masuda, H., Young, R. C., & Ozols, R. F. (1987) Proc. Am. Assoc. Cancer Res. 28, 291.
15. Hromas, R. A., North, J. A., & Burns, C. P. (1986) Proc. Am. Assoc. Cancer Res. 27, 263.
16. Johnson, N. P., Lapetoule, P., Razaka, H., & Villani, G. (1986) in Biochemical Mechanisms of Platinum Antitumor Drugs (McBrien, D. C. H., & Slater, T. F., Eds.) pp 1–28, IRL, Oxford.
17. Kraker, A. J., Steinkempt, R. W., & Moore, C. W. (1986) Proc. Am. Assoc. Cancer Res. 27, 286.
18. Meyn, R. E., Jenkins, S. F., & Thompson, L. H. (1982) Cancer Res. 42, 3106–3110.
19. Rawlings, C. J., & Roberts, J. J. (1986) Mutat. Res. 166, 157–168.
20. Richon, V. M., Schulte, N., & Eastman, A. (1987) Cancer Res. 47, 2056–2061.
21. Roberts, J. J., & Thomson, A. J. (1979) Prog. Nucleic Acid Res. Mol. Biol. 22, 71–133.
22. Roberts, J. J., Knox, R. J., Friedlos, F., & Lydall, D. A. (1986) in Biochemical Mechanisms of Platinum Antitumor Drugs (McBrien, D. C. H., & Slater, T. F., Eds.) pp 29–56, IRL, Oxford.
23. Sheibani, N., & Eastman, A. (1987) Proc. Am. Assoc. Cancer Res. 28, 314.
24. Strandberg, M. C., Bresnick, E., & Eastman, A. (1982) Chem.-Biol. Interact. 39, 169–180.
25. Zwelling, L. A., Filipski, J., & Kohn, K. W. (1979) Cancer Res. 39, 4989–4995.